Pathology, Inc. and CombiMatrix Expand Partnership in Prenatal Testing Market
20 Junio 2013 - 5:00AM
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company performing DNA-based testing services for developmental
disorders and cancer, today announced that it has been selected by
Pathology, Inc. to be its exclusive provider of chromosomal
microarray tests for the Products of Conception (POC) testing
market throughout the United States. POC testing, also referred to
as miscarriage testing, is a subset of the overall prenatal testing
market.
The announcement is an expansion of the previous strategic
partnership between the two companies announced in November 2012
that gave Pathology, Inc. the right to market and distribute
microarray tests on behalf of CombiMatrix in the states of
California and Nevada, as well as the St. Louis and Chicago
metropolitan areas.
"The partnership has been very beneficial for both parties to
date, and I believe it will benefit our physician partners
and their patients to extend the working relationship we have
established with CombiMatrix," said Vicki DiFrancesco, President
and CEO of Pathology, Inc., a full service, independent Women's
Health laboratory based in Torrance, California. "The POC market is
an important segment of women's health for Pathology, Inc. and we
are pleased to be working with an advanced laboratory like
CombiMatrix that specializes in microarray testing. We believe this
market is going to continue to expand as our physician customers
and their patients realize the importance of microarray testing in
helping to identify the causes of miscarriages and how that
information may assist in future pregnancies."
CombiMatrix President and Chief Executive Officer Mark McDonough
said, "The expansion of this partnership underscores the rapidly
expanding importance of microarray testing and the value our team
brings to Pathology, Inc. in terms of operational and analytical
support. Pathology, Inc. is one of the leading women's health
labs in the nation and we are very pleased to be recognized by
these experts as a valuable partner.
"Working closely with Pathology, Inc. allows us to extend our
customer base of OB/GYNs and provides us with additional marketing
and distribution support. Our relationship will only become more
important as the national healthcare market learns about the
benefits of chromosomal microarray testing," continued
McDonough.
About Pathology, Inc.
Pathology, Inc. is a full-service provider of anatomic and
clinical pathology testing services, with a 30-year foundation in
the Women's Health market. With expertise in molecular and digital
pathology, the Company has built a solid reputation for quality and
customer service with clients that include OB/Gyns, dermatologists,
urologists, gastroenterologists, and family practitioners, as well
as surgicenters, endoscopy centers, hospitals, and independent
laboratories. Pathology, Inc. is located at three separate
facilities; its Torrance headquarters, a second facility in
Templeton, CA (Central Coast Clinical Laboratories) and a third
laboratory in Wood Dale, IL. All three facilities are CLIA
certified and CAP accredited. Pathology, Inc.'s pathologists,
through its association with Affiliated Pathologists Medical Group
(APMG), are board certified and have a variety of multi-specialty
interests and expertise, as well as extensive cumulative experience
in outpatient pathology. Pathology, Inc. has provided pathology
services to physician offices and pathologists for over 25
years.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic
solutions and comprehensive clinical support for the highest
quality of care – specializing in miscarriage analysis, prenatal
and pediatric healthcare. CombiMatrix offers comprehensive testing
services for the detection of abnormalities of genes at the DNA
level beyond what can be identified through traditional
technologies. The Company performs genetic testing utilizing
microarray, FISH, PCR and G-Band chromosome analyses. Additional
information about CombiMatrix is available at www.combimatrix.com
or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not
limited to, statements regarding projected results of operations
and management's future business, operational and strategic plans,
momentum of our pre-natal and pediatric businesses, test menu
expansion, services and reports development and attracting greater
prenatal genetic screening business. These forward-looking
statements are not guarantees of future results and are subject to
risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in
any forward-looking statement. The risks and uncertainties
referred to above include, but are not limited to: our ability to
gain more market share, capitalize on markets and grow shareholder
value; our ability to successfully expand the base of our customers
and strategic partners, add to the menu of our diagnostic tests in
both of our primary markets, develop and introduce new tests and
related reports, optimize the reimbursements received for our
testing services, and increase operating margins by improving
overall productivity and expanding sales volumes; our ability to
successfully accelerate sales, steadily increase the size of our
customer rosters in both developmental medicine and oncology; lack
of growth in the developmental markets; our ability to attract and
retain a qualified sales force; rapid technological change in our
markets; changes in demand for our future products; the ability of
microarray technology to become the standard of care; legislative,
regulatory and competitive developments; general economic
conditions; and various other factors. Further information on
potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of
Form 10-Q, and in other filings with the Securities and Exchange
Commission. We undertake no obligation to revise or update
publicly any forward-looking statements for any reason, except as
required by law.
CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624
Media Contact:
Len Hall
VP, Media Relations
Allen & Caron
Tel (949) 474-4300
len@allencaron.com
Investor Relations Contact:
John Baldissera
BPC Financial Marketing
Tel (800) 368-1217
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2024 a Jul 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024